On Thu, Mar 5, 2009 at 3:11 PM, cardemaister <no_re...@yahoogroups.com> wrote: > > http://biopsychiatry.com/agomelatine/valdoxan.html > > Valdoxan®: A New Approach to > The Treatment of Depression > > First Melatonergic Agonist Antidepressant Shows > Efficacy and Tolerability Benefits Over Existing Therapies - > > Valdoxan® (agomelatine), the first melatonergic (MT1 and MT2 receptor) > agonist antidepressant, is an innovation in the treatment of depression with > several advantages over existing treatments according to data presented > during the 13th Congress of the Association of European Psychiatrists. > Besides being an effective antidepressant, Valdoxan has shown particular > advantages in improving the often disrupted sleep patterns of depressed > patients, without affecting daytime vigilance. >
Gee. I wonder how this would stack up against just your standard anti-depressant plus Roserem?
